Douglas Lane & Associates LLC Sells 24,970 Shares of Bristol Myers Squibb Company $BMY

Douglas Lane & Associates LLC decreased its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 1.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,539,425 shares of the biopharmaceutical company’s stock after selling 24,970 shares during the period. Douglas Lane & Associates LLC owned approximately 0.08% of Bristol Myers Squibb worth $69,428,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of BMY. Norges Bank acquired a new position in Bristol Myers Squibb during the second quarter worth about $1,554,154,000. Charles Schwab Investment Management Inc. boosted its position in Bristol Myers Squibb by 16.8% in the second quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock valued at $3,277,456,000 after buying an additional 10,195,775 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in shares of Bristol Myers Squibb by 428.5% during the second quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company’s stock worth $523,599,000 after buying an additional 9,171,098 shares during the last quarter. Man Group plc increased its holdings in shares of Bristol Myers Squibb by 280.4% during the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock worth $345,594,000 after buying an additional 5,503,391 shares in the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of Bristol Myers Squibb by 142.8% in the 2nd quarter. Franklin Resources Inc. now owns 8,436,811 shares of the biopharmaceutical company’s stock valued at $390,541,000 after acquiring an additional 4,961,869 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Trading Up 1.5%

BMY opened at $54.15 on Friday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $63.33. The company has a fifty day moving average of $47.73 and a 200-day moving average of $47.14. The stock has a market cap of $110.24 billion, a PE ratio of 18.29, a price-to-earnings-growth ratio of 8.29 and a beta of 0.29. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The business had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.75 billion. During the same quarter in the prior year, the firm posted $1.80 earnings per share. The business’s quarterly revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.7%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date of this dividend is Friday, January 2nd. Bristol Myers Squibb’s payout ratio is presently 83.78%.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers publicly announced an agreement with the U.S. government to improve affordability and access to medicines — a company release that frames the deal as preserving market access while responding to pricing pressures. This reduces regulatory uncertainty and the risk of punitive measures that could have hurt sales. Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
• Positive Sentiment: BMY and partner BioNTech reported progress in immunotherapy clinical programs (first-line liver cancer and a kidney‑cancer trial update), which add long-term commercial optionality if late‑stage data confirms benefit. These pipeline moves support upside beyond near‑term pricing headwinds. New Pumitamig Kidney Cancer Trial Adds Long-Term Optionality for Bristol-Myers Squibb and BioNTech
• Positive Sentiment: Analyst and media endorsements are visible: Guggenheim raised/maintained an elevated price target after an FDA priority review and media commentators (including Jim Cramer) are calling BMY a buy/value name — these signals can attract momentum and retail/institutional buyers. Guggenheim sets $62 target on Bristol-Myers Squibb Company (BMY) after FDA priority review
• Neutral Sentiment: Major press outlets report that nine pharma companies (including BMY) struck voluntary price agreements with the White House to link some U.S. prices to lower foreign prices and to avoid potential tariffs — this offers regulatory clarity but also implies longer‑term pricing pressure. Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
• Neutral Sentiment: Broader coverage (CNBC) confirms multiple large drugmakers are making similar deals with the administration — increases industry momentum toward pricing reforms but spreads the competitive/market impact across peers. Nine of the largest pharma companies ink deals with Trump to lower drug prices
• Neutral Sentiment: BMY set a Q4 2025 earnings release date (Feb. 5, 2026) — a near‑term catalyst investors will watch for sales impact from pricing agreements and pipeline progress. Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026
• Negative Sentiment: Analyst model updates from Zacks Research trimmed several near‑term EPS estimates and cut FY2027 estimates modestly, implying some downward revision risk to earnings expectations if pricing concessions or volume shifts persist. (Zacks research notes summarized across recent releases.)
• Positive Sentiment: Market commentary pieces positioning BMY as a long‑term value stock may attract defensive/value investors given the company’s dividend/cash flow profile and pipeline depth. Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Truist Financial set a $65.00 target price on Bristol Myers Squibb in a report on Wednesday, December 3rd. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $52.00 to $61.00 in a report on Monday, December 15th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Five analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $54.62.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.